Louis W J, Drummer O H, Tung L H
University of Melbourne, Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia.
Cardiovasc Drugs Ther. 1991 Jan;4 Suppl 6:1281-5. doi: 10.1007/BF00114234.
The pharmacology of celiprolol and its relationship to some other beta-adrenoceptor antagonists is described. Celiprolol is a potent beta blocker on beta 1-adrenoceptors and exhibits cardioselectivity both in vitro and in vivo in the pithed rat, but shows no significant in vitro alpha 1-blocking action. Celiprolol differs from atenolol in that it has an intrinsic sympathomimetic activity (ISA) for beta 1-adrenoceptors, which is reflected in its relative lack of negative inotropic effects in humans. In the pithed rat, celiprolol's ISA was demonstrated at much lower doses than for pindolol, even though pindolol has a similar potency to celiprolol in antagonizing the heart rate effects of isoproterenol. It was completely blocked by propranolol, indicating that celiprolol behaves like a partial agonist for beta 1-adrenoceptors, whereas the ISA developed by pindolol was only partially blocked by propranolol. These data suggest a different mechanism for the development of ISA between celiprolol and pindolol.
本文描述了塞利洛尔的药理学特性及其与其他一些β-肾上腺素能受体拮抗剂的关系。塞利洛尔是一种强效的β₁-肾上腺素能受体阻滞剂,在去大脑大鼠体内外均表现出心脏选择性,但在体外无明显的α₁-阻滞作用。塞利洛尔与阿替洛尔的不同之处在于,它对β₁-肾上腺素能受体具有内在拟交感活性(ISA),这反映在其对人体相对缺乏负性肌力作用。在去大脑大鼠中,塞利洛尔的ISA在比吲哚洛尔低得多的剂量下即可表现出来,尽管吲哚洛尔在拮抗异丙肾上腺素对心率的作用方面与塞利洛尔具有相似的效力。它被普萘洛尔完全阻断,表明塞利洛尔对β₁-肾上腺素能受体表现为部分激动剂,而吲哚洛尔产生的ISA仅被普萘洛尔部分阻断。这些数据提示塞利洛尔和吲哚洛尔产生ISA的机制不同。